PB

Priyanka Banthia

Active Director Director DIN 06931179
DIN 06931179 First appointment Jul 2014 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2014
Shareholding value •••• Premium profile

About Priyanka Banthia

Data last updated:

Priyanka Banthia is a Director at Sss Pharmachem Private Limited (since 2014). The company operates in Pharma. Sss Pharmachem Private Limited reported revenue of ₹17.51 Cr (FY 2025).

DIN 06931179
Primary Designation Director
Industry Pharma
First Appointment 22 Jul 2014
Oldest Company Age 19 yrs
Largest company Sss Pharmachem Private Limited · ₹17.51 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Sss Pharmachem Private Limited U24233GJ2007PTC050232
Director22 Jul 20142007₹17.51 Cr (FY 2025)Active

Board colleagues of Priyanka Banthia

Directorship timeline

Open interactive timeline →
Sss Pharmachem Private Limited
Premium access

Shareholding and investment profile for Priyanka Banthia

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Priyanka Banthia

Priyanka Banthia currently holds 1 directorship: Sss Pharmachem Private Limited (Director, since 22 Jul 2014, revenue ₹17.51 Cr (FY 2025)).

Priyanka Banthia was first appointed on 22 Jul 2014 as Director at Sss Pharmachem Private Limited.

The current boards of Priyanka Banthia's companies include Anil Kumar Baid (Sss Pharmachem Private Limited), Pramod Kumar Banthiya (Sss Pharmachem Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available